Endpoints News 24 feb 2026 Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market
Endpoints News 23 feb 2026 Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial
Endpoints News 9 feb 2026 Novo Nordisk sues Hims over Wegovy patent infringement, considers seeking 'hundreds of millions' in damages
Endpoints News 4 feb 2026 Embattled Novo Nordisk considers buying a monthly GLP-1 to bolster portfolio
Endpoints News 16 ene 2026 Novo Nordisk, BioMarin make AI moves; Bristol Myers welcomes neurology exec from Eisai
Endpoints News 15 ene 2026 A compounding pharmacy hits back at Eli Lilly, Novo Nordisk with antitrust lawsuit
Endpoints News 15 ene 2026 FDA to meet Novo Nordisk on troubled site; AbbVie buys drug-device factory
FierceBiotech 15 ene 2026 Novo Nordisk Foundation invests $860M in Danish institute nurturing homegrown biotechs
Endpoints News 15 ene 2026 Novo Nordisk Foundation to inject $850M+ into BioInnovation Institute through 2035
Endpoints News 12 ene 2026 #JPM26: Novo Nordisk CEO says pharma can learn from the GLP-1 compounding boom
Endpoints News 5 ene 2026 Novo Nordisk launches Wegovy pill at $25 per month for insured patients, $149 cash